What is microcystic adnexal carcinoma?
Microcystic adnexal carcinoma (MAC) is a rare, slow-growing skin cancer that starts in the sweat glands and hair follicle structures of the skin. These structures are known as the skin’s adnexa, which is where the name “adnexal” comes from.
MAC most often develops on the face, especially around the upper lip, nose, cheeks, chin and eyelids. It usually affects adults in middle or older age, with an average age of around 60 (Worley et al., 2019).
MAC rarely spreads to other parts of the body. However, it is locally aggressive: it grows sideways and deep into the skin, fat, muscle and along nerves, often far beyond the edges that can be seen or felt. This makes it easy to underestimate, and it can come back if not fully removed.
The cancer was first described as a distinct condition in 1982 (Goldstein, Barr and Santa Cruz, 1982). It is also called sclerosing sweat duct carcinoma, and the World Health Organization groups it with the other adnexal carcinomas of the skin.
The good news is that, when treated with careful, margin-controlled surgery, MAC can usually be cured, and long-term survival is excellent (Yu et al., 2010).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Rare, low-grade but locally aggressive sweat gland (adnexal) carcinoma |
| How common | Very rare |
| Typical age | Average about 60; can occur in younger adults and, rarely, children |
| Sex | Slightly more common in women |
| Main sites | Head and neck in about three-quarters, mostly the central face |
| Key signs | Slow-growing, firm, pale or skin-coloured patch, lump or scar-like area |
| Main treatment | Mohs micrographic surgery or surgery with complete margin assessment |
| Outlook | Excellent survival; local recurrence is the main risk |
2. Other names and related tumours
| Name | Notes |
|---|---|
| Microcystic adnexal carcinoma | The usual name |
| Sclerosing sweat duct carcinoma | Alternative name |
| Syringomatous carcinoma | Older or overlapping term |
| Malignant syringoma | Older term, no longer preferred |
Tumours that can look similar
| Tumour | Key differences |
|---|---|
| Morphoeic (infiltrative) basal cell carcinoma | The most common mimic; different staining pattern |
| Desmoplastic trichoepithelioma | Benign; small and superficial; does not invade deeply |
| Syringoma | Benign; small, multiple bumps, often around the eyes |
| Squamous cell carcinoma | Faster growing; different cells |
| Metastatic breast or other cancer | Spread from elsewhere; usually a known history |
3. Causes and risk factors
The exact cause of MAC is not known. Several factors appear to increase the risk:
| Risk factor | Notes |
|---|---|
| Sun exposure (ultraviolet light) | MAC is most common on sun-exposed skin of the face |
| Previous radiotherapy | Some cases arise years after radiotherapy to the head and neck, for example for acne or cancer in childhood |
| Weakened immune system | Organ transplant recipients and people on immune-suppressing medicines |
| Fair skin | MAC is more common in people with fair skin |
| Older age | Most people are diagnosed in their 50s to 70s |
Studies of the tumour’s genes have found TP53 mutations and changes in the JAK/STAT signalling pathway, including JAK1, in many cases (Chan et al., 2020). These changes are acquired in the tumour, not inherited.
MAC is not contagious and is not passed on in families.
4. How does it look
On the skin
MAC often looks harmless, which is one reason it may be diagnosed late.
| Feature | Description |
|---|---|
| Shape | A flat or slightly raised patch (plaque), a small lump (nodule) or a scar-like area |
| Colour | Skin-coloured, white, yellowish or pale pink |
| Surface | Usually smooth; may have tiny cysts or fine blood vessels; ulceration is uncommon |
| Edges | Poorly defined; hard to tell where it ends |
| Feel | Firm or hard, like a scar, often more extensive than it looks |
| Growth | Very slow, over months to years |
| Location | Upper lip, around the nose, cheek, chin, eyelids, forehead and scalp |
The patch may be mistaken for a scar, a cyst or a benign growth. Pressing on it may reveal that the firm area extends much further than the visible change.
Under the microscope
| Feature | Description |
|---|---|
| Upper layers | Small cysts filled with keratin and nests of basaloid cells, resembling hair follicles |
| Deeper layers | Small ducts and strands of cells within dense, scar-like (sclerotic) tissue |
| Depth | Extends deep into fat, muscle and sometimes bone |
| Perineural invasion | Growth along nerves is common |
| Cells | Look bland, with few dividing cells, despite the aggressive growth |
| Stains | Cytokeratins such as CK7 and CK15 support the diagnosis |
A superficial biopsy may show only harmless-looking cysts and miss the cancer. For this reason, a deep biopsy that reaches the fat under the skin is recommended (Worley et al., 2019).
On scans
Scans are not needed for most small MACs, because the tumour is usually confined to the skin and the tissue just beneath it. MRI can help show deep spread or growth along nerves in large, recurrent or eye-area tumours.
5. Symptoms
Many people with MAC have few or no symptoms apart from the slowly changing skin patch.
Common symptoms
- A slowly growing, firm patch or lump on the face
- A scar-like area that appears without injury
- Change in the shape of the lip, nose or eyelid
Symptoms of nerve involvement
| Symptom | Notes |
|---|---|
| Numbness | Reduced feeling in the skin around the lesion |
| Tingling or “pins and needles” | A sign of growth along nerves |
| Burning or pain | May be the first symptom in some people |
| Itching | Sometimes present |
Symptoms of advanced disease
- Pulling of the eyelid or difficulty closing the eye
- Facial weakness, rarely, if the facial nerve is involved
- A lump in the neck if lymph nodes are involved, which is very rare
When to seek medical advice
See a doctor or dermatologist if you notice a firm, scar-like patch or lump on the face that is slowly growing, especially if it causes numbness, tingling or burning.
Tell your doctor if you have had radiotherapy to the head or neck in the past, or if you take medicines that weaken the immune system.
6. Diagnosis
| Test | Purpose |
|---|---|
| Skin examination | Assesses the size and feel of the lesion |
| Dermoscopy | A magnified look at the skin surface |
| Deep incisional or punch biopsy | The key test; must include tissue below the skin |
| Examination by a dermatopathologist | Distinguishes MAC from basal cell carcinoma and benign tumours |
| MRI | For large, recurrent or eyelid tumours, or suspected nerve spread |
| Lymph node examination | Usually by examination; scans only if nodes are enlarged |
Diagnosis can be difficult, and MAC is often initially misdiagnosed. In one Mohs surgery series, around a third of tumours had first been diagnosed as basal or squamous cell carcinoma (Leibovitch et al., 2005).
7. Treatment
MAC should be treated by a team experienced in complex skin cancers, often including a Mohs surgeon, a plastic or oculoplastic surgeon and a radiation oncologist. Evidence-based guidelines published in 2019 guide care (Worley et al., 2019).
Surgery
| Treatment | Description |
|---|---|
| Mohs micrographic surgery | The tumour is removed layer by layer, and 100% of the edges are checked under the microscope while the patient waits; repeated until clear |
| Surgery with complete margin assessment | Similar principle, with all edges examined in the laboratory before reconstruction |
| Standard wide local excision | Higher risk of leaving tumour behind and of recurrence (Chaudhari et al., 2016) |
Mohs surgery has the lowest recurrence rates. In one series, only 1 of 20 patients followed for five years had a recurrence (Leibovitch et al., 2005).
Because MAC extends further than expected, the wound can be larger than the visible lesion. Reconstruction may involve stitches, a skin flap or a skin graft.
Radiotherapy
| Situation | Role |
|---|---|
| After surgery | For tumours with nerve involvement, unclear margins or high recurrence risk |
| When surgery is not possible | As the main treatment in people who cannot have surgery |
| Recurrent tumours | Sometimes combined with surgery |
Other treatments
Chemotherapy has not been shown to work well for MAC (Chaudhari et al., 2016). For rare cases with spread, treatment is planned individually, often within clinical trials.
Special situations
| Situation | Approach |
|---|---|
| Eyelid or around the eye | Surgery with an oculoplastic surgeon; aims to protect the eye and eyelid function |
| Lip | Reconstruction aims to keep the lip working for eating and speech |
| Older or frail people | Radiotherapy alone, or careful observation for very slow-growing tumours |
| Transplant recipients | Review of immune-suppressing medicines with the transplant team; closer skin checks |
Why margin control matters
MAC sends out thin strands of tumour cells deep into the tissue and along nerves. With standard surgery, only a small sample of the edges is checked, so these strands can be missed. Mohs surgery and similar techniques examine the entire edge of the removed tissue, allowing the surgeon to follow the tumour exactly and remove it with as little healthy skin as possible.
After surgery
| Topic | What to expect |
|---|---|
| Wound care | Keep the area clean and follow dressing advice |
| Swelling and bruising | Common around the eyes and lips for a week or two |
| Scarring | Improves over months; scar treatments can help |
| Numbness | May remain if nerves were involved |
8. Outlook (prognosis)
The overall outlook for MAC is excellent. In a large US database study, 10-year relative survival was about 98%, and spread to lymph nodes occurred in only about 1% of people (Yu et al., 2010).
| Factor | Effect on outlook |
|---|---|
| Complete removal with clear margins | Very low risk of recurrence |
| Mohs or complete margin surgery | Lowest recurrence rates |
| Standard excision with unclear margins | Higher recurrence risk |
| Growth along nerves | Higher recurrence risk |
| Large or recurrent tumours | More extensive surgery needed; higher recurrence risk |
| Spread to lymph nodes or distant organs | Very rare |
The main problem is local recurrence, which can occur many years after treatment. Recurrent MAC is usually still treatable with further surgery or radiotherapy.
9. Follow-up
The guidelines recommend review by a doctor familiar with MAC every 6-12 months for at least the first 5 years after treatment (Worley et al., 2019).
| Follow-up | Purpose |
|---|---|
| Examination of the scar and surrounding skin | Look for recurrence |
| Full skin check | Many people with MAC also have other sun-related skin cancers |
| Lymph node check | Rarely needed, but part of routine examination |
| MRI | If symptoms such as new numbness or pain develop |
10. Living with MAC
- Protect your skin from the sun with clothing, hats and broad-spectrum sunscreen
- Check your skin regularly, including the treated area, and report changes
- Report new numbness, tingling or pain near the scar
- Ask about scar care and, if needed, cosmetic camouflage
- Seek support if changes to your face affect your confidence; specialist nurses and support groups can help
- Tell your doctors about the diagnosis if you start immune-suppressing medicines
- Take photographs of the treated area every few months, which can help you and your doctor notice slow changes
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is MAC dangerous? | It rarely spreads or shortens life, but it can grow deeply and damage the face if untreated |
| Why was it first thought to be a scar or basal cell carcinoma? | MAC looks harmless and can resemble other conditions, especially on shallow biopsies |
| Why was my wound bigger than the spot? | MAC grows beneath the skin far beyond the visible edges |
| Will it come back? | The risk is low after Mohs surgery with clear margins, but follow-up is still important |
| Is it caused by the sun? | Sun exposure is thought to play a role, along with previous radiotherapy and a weak immune system |
| Is it inherited? | No |
| Can MAC appear in more than one place? | Rarely; most people have a single tumour, but regular skin checks are advised because other sun-related skin cancers are common |
| Will I need a general anaesthetic? | Mohs surgery is usually done under local anaesthetic; larger reconstructions may need a general anaesthetic |
12. Questions to ask your care team
- Was the biopsy deep enough to confirm the diagnosis?
- Can I have Mohs surgery or surgery with complete margin checking?
- How big is the wound likely to be, and how will it be repaired?
- Is there any sign of nerve involvement?
- Will I need radiotherapy after surgery?
- How often should I have follow-up visits?
Resources
- Chan, M.P. et al. (2020) ‘Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas’, Modern Pathology, 33(6), pp. 1092-1103.
- Chaudhari, S.P. et al. (2016) ‘Treatments for microcystic adnexal carcinoma: a review’, Journal of Dermatological Treatment, 27(3), pp. 278-284.
- Goldstein, D.J., Barr, R.J. and Santa Cruz, D.J. (1982) ‘Microcystic adnexal carcinoma: a distinct clinicopathologic entity’, Cancer, 50(3), pp. 566-572.
- Leibovitch, I. et al. (2005) ‘Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery’, Journal of the American Academy of Dermatology, 52(2), pp. 295-300.
- Worley, B. et al. (2019) ‘Evidence-based clinical practice guidelines for microcystic adnexal carcinoma: informed by a systematic review’, JAMA Dermatology, 155(9), pp. 1059-1068.
- Yu, J.B. et al. (2010) ‘Surveillance, Epidemiology, and End Results (SEER) database analysis of microcystic adnexal carcinoma (sclerosing sweat duct carcinoma) of the skin’, American Journal of Clinical Oncology, 33(2), pp. 125-127.
Prepared by the editorial team, October 2026.
M